BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

10243

539268

SYNGENE

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

SYNGENE INTERNATIONAL LTD performance

Today’s low

Today’s high

₹ 626.00 ₹ 640.50
₹ 634.05

52 week low

52 week high

₹ 607.65 ₹ 960.60
₹ 634.05

Open Price

₹ 630.00

Prev. Close

₹ 628.90

Volume (Shares)

2090137.00

Total traded value

₹ 13252.51

Upper Circuit

₹ 691.75

Lower Circuit

₹ 566.05

info

SYNGENE INTERNATIONAL LTD Share Price Update

As of the latest trading session, SYNGENE INTERNATIONAL LTD share price is currently at ₹ 634.05, which is up by ₹ 5.14 from its previous closing. Today, the stock has fluctuated between ₹ 626.00 and ₹ 640.50. Over the past year, SYNGENE INTERNATIONAL LTD has achieved a return of -7.99 %. In the last month alone, the return has been -11.71 %. Read More...

SYNGENE INTERNATIONAL LTD fundamentals


  • Market cap (Cr)

    25,489.76

  • P/E Ratio (TTM)

    54.44

  • Beta

    0.65

  • Book Value / share

    115.24

  • Return on equity

    11.95%

  • EPS (TTM)

    11.03

  • Dividend yield

    0.20%

  • Net profit/quarter (Cr)

    174.40

info icon alternate text
  • Market cap (Cr)

    25,367.15

  • P/E Ratio (TTM)

    54.44

  • Beta

    0.64

  • Book Value / share

    115.24

  • Return on equity

    11.95%

  • EPS (TTM)

    11.03

  • Dividend yield

    0.20%

  • Net profit/quarter (Cr)

    174.40

info icon alternate text

SYNGENE INTERNATIONAL LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 948.40
Operating Expense 738.10
Net Profit 174.40
Net Profit Margin (%) 18.38
Earnings Per Share (EPS) 4.34
EBITDA 328.40
Effective Tax Rate (%) 23.74
Particulars DEC 2024 (Values in Cr)
Revenue 877.10
Operating Expense 725.30
Net Profit 123.10
Net Profit Margin (%) 14.03
Earnings Per Share (EPS) 3.07
EBITDA 268.80
Effective Tax Rate (%) 27.50
Particulars SEP 2024 (Values in Cr)
Revenue 821.30
Operating Expense 713.40
Net Profit 96.60
Net Profit Margin (%) 11.76
Earnings Per Share (EPS) 2.41
EBITDA 225.00
Effective Tax Rate (%) 22.28
Particulars JUN 2024 (Values in Cr)
Revenue 726.50
Operating Expense 677.40
Net Profit 73.90
Net Profit Margin (%) 10.17
Earnings Per Share (EPS) 1.84
EBITDA 197.90
Effective Tax Rate (%) 25.20
Particulars MAR 2024 (Values in Cr)
Revenue 864.70
Operating Expense 669.60
Net Profit 189.80
Net Profit Margin (%) 21.94
Earnings Per Share (EPS) 4.73
EBITDA 314.60
Effective Tax Rate (%) 9.79
Particulars MAR 2025 (Values in Cr)
Revenue 3373.30
Operating Expense 2854.20
Net Profit 468.00
Net Profit Margin (%) 13.87
Earnings Per Share (EPS) 11.64
EBITDA 1020.10
Effective Tax Rate (%) 24.71
Particulars MAR 2024 (Values in Cr)
Revenue 3203.10
Operating Expense 2722.70
Net Profit 466.50
Net Profit Margin (%) 14.56
Earnings Per Share (EPS) 11.62
EBITDA 955.69
Effective Tax Rate (%) 16.29
Particulars MAR 2023 (Values in Cr)
Revenue 3193.50
Operating Expense 2663.50
Net Profit 473.00
Net Profit Margin (%) 14.81
Earnings Per Share (EPS) 11.81
EBITDA 1005.20
Effective Tax Rate (%) 21.28
Particulars MAR 2022 (Values in Cr)
Revenue 2601.40
Operating Expense 2141.79
Net Profit 393.80
Net Profit Margin (%) 15.13
Earnings Per Share (EPS) 9.89
EBITDA 815.50
Effective Tax Rate (%) 18.24
Particulars MAR 2021 (Values in Cr)
Revenue 2179.40
Operating Expense 1811.60
Net Profit 403.70
Net Profit Margin (%) 18.52
Earnings Per Share (EPS) 10.15
EBITDA 769.59
Effective Tax Rate (%) 13.62
Particulars MAR 2024 (Values in Cr)
Book Value / Share 104.27
ROE % 11.95
ROCE % 12.51
Total Debt to Total Equity 0.12
EBITDA Margin 29.84
Particulars MAR 2023 (Values in Cr)
Book Value / Share 90.16
ROE % 13.69
ROCE % 14.07
Total Debt to Total Equity 0.24
EBITDA Margin 31.48
Particulars MAR 2022 (Values in Cr)
Book Value / Share 82.14
ROE % 12.89
ROCE % 11.72
Total Debt to Total Equity 0.31
EBITDA Margin 31.35
Particulars MAR 2021 (Values in Cr)
Book Value / Share 70.46
ROE % 16.17
ROCE % 13.50
Total Debt to Total Equity 0.33
EBITDA Margin 35.31
Particulars MAR 2020 (Values in Cr)
Book Value / Share 54.35
ROE % 17.28
ROCE % 15.02
Total Debt to Total Equity 0.38
EBITDA Margin 34.57
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 563.50
Total Assets 6151.60
Total Liabilities 6151.60
Total Equity 4257.80
Share Outstanding 402015000
Price to Book Ratio 6.73
Return on Assets (%) 8.29
Return on Capital (%) 11.59
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 531.70
Total Assets 5831.00
Total Liabilities 5831.00
Total Equity 3618.00
Share Outstanding 401434500
Price to Book Ratio 6.59
Return on Assets (%) 7.96
Return on Capital (%) 11.07
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 517.90
Total Assets 5563.80
Total Liabilities 5563.80
Total Equity 3297.60
Share Outstanding 400796500
Price to Book Ratio 7.27
Return on Assets (%) 7.11
Return on Capital (%) 9.68
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 642.60
Total Assets 4883.20
Total Liabilities 4883.20
Total Equity 2821.40
Share Outstanding 400000000
Price to Book Ratio 7.71
Return on Assets (%) 8.29
Return on Capital (%) 11.27
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 281.50
Total Assets 4162.90
Total Liabilities 4162.90
Total Equity 2175.80
Share Outstanding 400000000
Price to Book Ratio 4.44
Return on Assets (%) 9.89
Return on Capital (%) 16.59
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 528.20
Total Assets 5833.90
Total Liabilities 5833.90
Total Equity 4191.50
Share Outstanding 402015000
Price to Book Ratio 6.73
Return on Assets (%) 7.99
Return on Capital (%) 10.77
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 509.30
Total Assets 5848.00
Total Liabilities 5848.00
Total Equity 3618.90
Share Outstanding 401434500
Price to Book Ratio 6.59
Return on Assets (%) 8.08
Return on Capital (%) 11.28
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 515.10
Total Assets 5560.80
Total Liabilities 5560.80
Total Equity 3292.00
Share Outstanding 400796500
Price to Book Ratio 7.27
Return on Assets (%) 7.08
Return on Capital (%) 9.65
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 638.20
Total Assets 4877.50
Total Liabilities 4877.50
Total Equity 2818.30
Share Outstanding 400000000
Price to Book Ratio 7.71
Return on Assets (%) 8.27
Return on Capital (%) 11.24
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 280.30
Total Assets 4162.00
Total Liabilities 4162.00
Total Equity 2174.10
Share Outstanding 400000000
Price to Book Ratio 4.44
Return on Assets (%) 9.88
Return on Capital (%) 16.57
Particulars MAR 2024 (Values in Cr)
Net Income 510.00
Cash from Operations 1167.20
Cash from Investing -495.60
Cash from Financing -551.50
Net change in Cash -5.00
Free Cash Flow 1659.20
Particulars MAR 2023 (Values in Cr)
Net Income 464.40
Cash from Operations 960.30
Cash from Investing -656.40
Cash from Financing -342.50
Net change in Cash -175.40
Free Cash Flow 1466.90
Particulars MAR 2022 (Values in Cr)
Net Income 395.80
Cash from Operations 686.40
Cash from Investing -611.50
Cash from Financing -31.30
Net change in Cash -62.20
Free Cash Flow 1161.70
Particulars MAR 2021 (Values in Cr)
Net Income 404.90
Cash from Operations 784.80
Cash from Investing -628.10
Cash from Financing 58.00
Net change in Cash 131.10
Free Cash Flow 1225.60
Particulars MAR 2020 (Values in Cr)
Net Income 412.10
Cash from Operations 784.20
Cash from Investing -428.40
Cash from Financing -225.50
Net change in Cash 23.20
Free Cash Flow 1414.20
Particulars MAR 2024 (Values in Cr)
Net Income 466.50
Cash from Operations 1011.80
Cash from Investing -383.50
Cash from Financing -536.30
Net change in Cash -6.40
Free Cash Flow 1362.69
Particulars MAR 2023 (Values in Cr)
Net Income 473.00
Cash from Operations 972.10
Cash from Investing -688.20
Cash from Financing -340.20
Net change in Cash -190.00
Free Cash Flow 1493.50
Particulars MAR 2022 (Values in Cr)
Net Income 393.80
Cash from Operations 686.40
Cash from Investing -611.50
Cash from Financing -31.30
Net change in Cash -60.60
Free Cash Flow 1161.70
Particulars MAR 2021 (Values in Cr)
Net Income 403.70
Cash from Operations 780.80
Cash from Investing -628.10
Cash from Financing 58.00
Net change in Cash 127.90
Free Cash Flow 1221.60
Particulars MAR 2020 (Values in Cr)
Net Income 411.50
Cash from Operations 783.80
Cash from Investing -428.40
Cash from Financing -225.50
Net change in Cash 23.50
Free Cash Flow 1413.80
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 76.41 13.35 100103.60 5690.80 / 7545.10
FORTIS MALAR HOSPITALS LIMITED 75.38 183.85 4.73 141.28 51.01 / 98.70
SHREE PACETRONIX LTD. 70.00 14.58 1.87 25.20 61.11 / 268.50
TRANSGENE BIOTEK LTD. 3.68 0.00 2.57 27.88 3.22 / 10.84
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 83.30 12.22 100103.60 5690.80 / 7545.10
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 32.25 0.00 -17.27 24.09 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5560.50 29.47 6.24 6083.19 3750.00 / 6400.00

SYNGENE INTERNATIONAL LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
634.05 0.81 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 644.70
  • 26 Days 690.00
  • 10 Days 666.10
  • 50 Days 708.80
  • 12 Days 671.70
  • 100 Days 743.40
  • 20 Days 684.60
  • 200 Days 768.00
624.28 PIVOT

First Support

616.87

First Resistance

636.32

Second Support

604.83

Second Resistance

643.73

Third Support

597.42

Third Resistance

655.77

RSI

35.59

ADX

17.57

MACD

-18.27

Williams % R

-84.71

Commodity Channel Index (CCI)

-130.43

Date

2025-04-30

Week

2838739.00

Same Day

1260021.00

Month

1182923.00

1 Year

0.66

3 Year

0.64

Over 1 Month

-11.71%

down

Over 1 Year

-7.99%

down

Over 3 Months

-16.53%

down

Over 3 Years

0.74%

down

Over 6 Months

-26.43%

down

Over 5 Years

14.50%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

SYNGENE INTERNATIONAL LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
6.29%
Promoter Holdings
52.73%
FII
19.46%
DII
21.5%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Biocon Limited 2.11185608E8 (52.46%) Shareholding of Promoter and Promoter Group
Icici Prudential Innovation Fund 2.0639918E7 (5.13%) Public Shareholding
Mirae Asset Equity Savings Fund 1.5877366E7 (3.94%) Public Shareholding
Government Of Singapore 1.1837989E7 (2.94%) Public Shareholding
Government Pension Fund Global 9994155.0 (2.48%) Public Shareholding
Nippon Life India Trustee Ltd-a/c Nippon India Fle 7546644.0 (1.87%) Public Shareholding
Uti Nifty Midsmallcap 400 Momentum Quality 100 Ind 7349289.0 (1.83%) Public Shareholding
Lici New Endowment Plus-growth Fund 7183419.0 (1.78%) Public Shareholding
Dsp Nifty Healthcare Etf 4520994.0 (1.12%) Public Shareholding
Biocon Limited Employee Welfare Trust (murali Krishnan K N And K Nanda Kumar) 1053633.0 (0.26%) Shareholding of Promoter and Promoter Group
Kiran Mazumdar Shaw 21964.0 (0.01%) Shareholding of Promoter and Promoter Group
Dev Mazumdar 13686.0 (0.0%) Shareholding of Promoter and Promoter Group
Biocon Research Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ravi Rasendra Mazumdar 8806.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

SYNGENE INTERNATIONAL LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
30 Jun 2023 0.5 Final 30 Jun 2023 Equity shares
30 Jun 2023 0.75 Special 30 Jun 2023 Equity shares
30 Jun 2022 0.5 Final 01 Jul 2022 Equity shares
30 Jun 2022 0.5 Special 01 Jul 2022 Equity shares
16 Jul 2019 0.5 Final 17 Jul 2019 Equity shares
17 Jul 2018 1.0 Final 18 Jul 2018 Equity shares
20 Jul 2017 1.0 Final 21 Jul 2017 Equity shares
17 Mar 2016 1.0 Interim 19 Mar 2016 Equity shares
Ex-Date Ex-Bonus Ratio
12 Jun 2019 11 Jun 2019 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
28 Jun 2024 1.25 Final 28 Jun 2024 Equity shares
30 Jun 2023 0.5 Final 30 Jun 2023 Equity shares
30 Jun 2023 0.75 Special 30 Jun 2023 Equity shares
30 Jun 2022 0.5 Final 01 Jul 2022 Equity shares
30 Jun 2022 0.5 Special 01 Jul 2022 Equity shares
16 Jul 2019 0.5 Final 17 Jul 2019 Equity shares
17 Jul 2018 1.0 Final 18 Jul 2018 Equity shares
20 Jul 2017 1.0 Final 21 Jul 2017 Equity shares
17 Mar 2016 1.0 Interim 19 Mar 2016 Equity shares
Ex-Date Ex-Bonus Ratio
12 Jun 2019 11 Jun 2019 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

SYNGENE INTERNATIONAL LTD Share Price

Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Headquartered in India, the operations are driven by its highly qualified teams comprising ~6000 scientists and its state-of-the-art facilities, spread over 2.2 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore. The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers.

Syngene International Limited was incorporated at Bangalore in 1993. The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited. The Company's health-related services extend across all major therapeutic areas and modalities. It provides end-to-end services within the Contract Research Organization (CRO) and a growing range of services within the Contract Development and Manufacturing Organization (CDMO). The primary target market for these services is the pharmaceutical and biotechnology (biotech) sectors. The same scientific capabilities that serve human health also serve nutrition, animal health, consumer goods, agri-chemicals, and specialty chemical sectors.

During the year 1994-1995, the company pioneered in CRO services for both Chemistry and Biology.

During the year 2001-2002, the company acquired a new facility inclusive of a cGMP pilot plant. In March 30, 2002, the company's 99.9% equity share was transferred to Biocon and the company became a subsidiary of Biocon Ltd.

During the year 2003-2004, the company introduced Process Research and Optimization Services. In October 21, 2004, the company commissioned a new research facility at Boammasandra, Bangalore.

In February 15, 2006, the company commissioned new facility at Biocon Park. In August 30, 2006, the company received approval of additional facility to set up as SEZ unit from Cochin Special Economic Zone.

During the year 2006-2007, Bristol- Myers Squibb had entered into a long term agreement with the company to set up an exclusive research facility to house more than 400 scientists. During the year, the company had ventured into other area of Biology viz Genetic Engineering, Protein Chemistry, and assay development. The company had developed extensive expertise in the creation of customized stable cell lines expressing proteins / receptors of intersest.

During the year 2007-2008, the company entered a long term service agreement with BMS. During the year 2008-2009, the company created an alliance partnership with DuPont Crop Protection.

On 21 July 2011, Syngene International and Endo Pharmaceuticals USA announced that they have signed an agreement to expand their collaboration to develop novel biological therapeutic molecules against cancer. Syngene and Endo will partner on two new discovery programmes, strengthening their ongoing alliance in cancer research. Under the agreement, Endo will retain all rights to the molecules developed, while Syngene International will receive research fees, milestone payments and success fees from Endo.

On 4 June 2012, Abbott, one of India's largest healthcare companies, inaugurated its first nutrition research and development center in the country, in collaboration with Syngene International. The state-of-the-art Research and Development center will focus on the development of science-based, affordable nutrition products for the country and enable the expansion of Abbott's nutrition product portfolio.

In 2012, Syngene International received ANVISA Certification of clinical facilities. During the year under review, Syngene International acquired 100% stake in Clinigene International Limited from Biocon.

Syngene International crossed an annual turnover of Rs 500 crore crore in the year ended 31 March 2013.

In 2013, Baxter International Inc. collaborated with Syngene International to establish the Baxter Global Research Center'. During the year under review, Syngene International's Control Testing Laboratory received acceptance from the Department of Health & Human Services, US Food and Drug Administration.

On 3 June 2014, Bristol-Myers Squibb and Syngene International announced a five-year extension of their drug discovery and development collaboration in India. Financial terms were not disclosed.

In 2014, Syngene International's API manufacturing facility received acceptance from Department of Health & Human Services, US Food and Drug Administration. During the year under review, Syngene International established a 75,000 sq. ft. centre to provide stability and analytical services.

Syngene International made its debut on the secondary equity market on 11 August 2015. The stock debuted at Rs 295 on BSE, a premium of 18% compared to the initial public offer (IPO) price of Rs 250 per share. The Rs 550-crore Initial Public Offering (IPO) through offer for sale from its parent Biocon Ltd. received an excellent response from investors and was subscribed 32.05 times. The issue opened for subscription on 27 July 2015 and closed on 29 July 2015.

In 2015, Syngene International's subsidiary Clinigene International Limited, which provides clinical research and clinical trial services, was amalgamated with Syngene International.

Syngene International crossed annual turnover of Rs 1000 crore in the year ended 31 March 2016.

On 6 September 2016, Syngene International announced the establishment in Bangalore, India, of an integrated, multi-disciplinary drug discovery and development center for Amgen, Inc. The state-of-the-art dedicated center will be staffed by a team of more than 100 highly qualified Syngene scientists, working in close association with Amgen researchers around the world on the discovery and development of innovative medicines. In addition to being customized to meet Amgen's functional requirements, the facility complies with the highest regulatory standards. Its design includes a range of environmentally-friendly features and flexible layouts, and is configured to minimize solvent and effluent waste with a strong emphasis on laboratory safety and 'green' chemistry.

On 21 September 2016, Syngene International Ltd.and Strand Life Sciences announced that they have completed a deal through which Syngene has purchased assets of Strand Life Sciences related to systems biology, Heptox and pharma bioinformatics services. This includes target dossier business and rights to NGS data analytics and Sarchitect platforms, supported by a strong scientific team. Financial details of the deal were not disclosed.

This deal gives Syngene access to Strand's patented Virtual Liver model and the NGS analytics platform. The Virtual Liver model is able to predict the toxic effect of different drugs or chemicals on the liver (both rat and human) using information from laboratory-based experiments prior to actual testing on live animals or humans. Strand NGS is an integrated platform that provides analysis, management and visualization tools for next-generation sequencing data.

On 2 March 2017, Herbalife, a global nutrition company, announced the launch of its first Nutrition Research and Development Lab in India, in partnership with Syngene International. The strategic partnership will help Herbalife Nutrition develop and formulate world-class nutrition products for Indian consumers.

On 27 July 2017, Syngene International announced the expansion of its research collaboration with Amgen Inc. As a result, Syngene will expand the Syngene Amgen Research & Development Center (SARC) in terms of size and scope of its operations. The expansion of SARC will be customized to meet Amgen's functional requirements and will include a range of environment-friendly features that will enable optimal utilization of the laboratory space.

On 14 November 2017, Syngene International announced that it has expanded its ongoing collaboration with Bristol-Myers Squibb. The next phase of the partnership will see the addition of a new facility to support future Bristol-Myers Squibb research and development operations, an expansion of the team and the extension of the existing agreement through 2026. As part of the expansion, Syngene will set up a new dedicated facility spread across 25,000 sq. ft. of laboratory and office space for Bristol-Myers Squibb. This facility will house an additional team of 75 Syngene scientists who will work exclusively in support of Bristol-Myers Squibb.

On 26 March 2018, Syngene International announced an R&D agreement with GSK, a science-led global healthcare company. The multiyear agreement will focus on accelerating the discovery of new drug candidates using Syngene's discovery services platforms. As part of the agreement, Syngene will set-up a customized discovery research laboratory to support projects across several therapeutic areas. A team of Syngene scientists will work closely with GSK's global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world's most pressing healthcare needs.

On 30 May 2018, Syngene International announced that the company has entered into a non-exclusive partnering agreement with Zumutor Biologics, an emerging immuno-oncology company, to access Zumutor's proprietary human phage/yeast display library. This collaboration further enhances Syngene's market-leading capabilities in Discovery Biology, providing its scientists with additional tools to help solve complex biology problems in biotherapeutic drug discovery. Under the terms of the agreement, Syngene will screen target antigens against Zumutor's proprietary human antibody libraries to identify and characterize novel antibody clones, which will be further developed by Syngene towards novel biotherapeutics programs for its partners

During year 2018-19, the Company commissioned Phase I of its upgraded S2 facility, which brings on board 105,000 sq. ft of space. The Company's Dedicated R&D Centres gained from the extension of the multi-year agreement up to 2024 with Baxter Healthcare Corporation, a global healthcare company. In line with the revised agreement, a new laboratory was commissioned, and the strength of the scientific team supporting Baxter was increased. In line with the contract expansion and extension with Bristol-Myers Squibb (BMS), a multinational pharmaceutical company, Syngene commissioned a new research facility spread across 25,000 sq. ft. of laboratory and office space during the year. The Amgen dedicated centre houses around 75 Syngene scientists. The Company completed the development and clinical supplies manufacturing of a drug product for Amgen. The Company's research collaboration with GSK, signed in FY18, became operational during the year.

In year 2019-20, the Company developed and validated a Human Papilloma Virus (HPV) assay, a test system increasingly being used for cervical cancer screening.

During year 2020-21, the Company commissioned the first phase of new R&D centre in Hyderabad. It commenced API manufacturing facility in Mangaluru and expanded the R&D facility in Bengaluru. Two 2KL bioreactors were commissioned during the year and a microbial manufacturing facility was set up, to strengthen biologics manufacturing capacity.

During year 2021-22, the Company expanded its research facilities in Bangalore and Hyderabad. As part of the third phase
of expansion, capacity for 300 scientists was added in Hyderabad, taking the total capacity to around 600 scientists. It also invested in enhancing its scientific capabilities to both sustain as a service provider for fully integrated therapeutic discovery. The Research Informatics unit launched a drug discovery informatics platform to empower the scientists with project information and tools to generate and evaluate hypotheses. The Company signed a five-year agreement with IAVI1 , a USAbased, non-profit, scientific research organization to develop and manufacture three recombinant, monoclonal antibodies (mAbs) for Human Immunodeficiency Virus (HIV). A cGMP microbial manufacturing facility with 500-liter capacity was commissioned in 2021. A fourth additional 2,000-liter single-use bioreactor was introduced to the mammalian biologics facility.

During the year 2022-23, Syngene's second campus in Discovery Chemistry operations in Hyderabad grew to over 900 scientists. It commissioned a new PROTAC lab in Hyderabad; commissioned a kilo lab to expedite formulation and process development work and a state-of-the-art sterile Fill-Finish facility for smallscale clinical manufacturing; commissioned the advancement of Amgen's R&D projects.

In FY23, the Company launched new differentiated platforms such as SynTACs (targeted degradation), SARchitect (data analysis and virtual collaboration), and SynTIPS (data analysis related to biological targets and pathways). Additionally, existing platforms, Syn.AI (AI-enhanced therapeutic R&D) and SynVent (integrated drug discovery), were enhanced further. The construction of a state-of-the-art, fillfinish facility for sterile injectable drugs was commissioned. The commercial manufacturing of drug substance for Zoetis was started. In addition to growing capabilities in monoclonal antibodies, the portfolio expanded for GMP manufacturing of plasmid DNA and mRNA.

In 2024, Company purchased a 17-acre land parcel in Genome Valley, Hyderabad, to expand research operations. It also added biologics assay capability at the Hyderabad campus to complement the existing Drug Metabolism & Pharmacokinetics (DMPK) and Compound
Management facilities. It commissioned a non-GMP facility in Bangalore to do early-phase development projects. It made good progress with Zoetis and commissioned a state-of-the art, digitally-enabled Quality Control laboratory to support the growing biologics operations. It acquired a biologics manufacturing facility from Stelis Biopharma Ltd.

Parent organization Indian Private
NSE symbol SYNGENE
Founded 1993
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Syngene International Ltd?

Answer Field

The share price of Syngene International Ltd for NSE is ₹ 634.05 and for BSE is ₹ 631.

What is the Market Cap of Syngene International Ltd?

Answer Field

The market cap of Syngene International Ltd for NSE is ₹ 2,54,89.76 Cr. and for BSE is ₹ 2,53,67.15 Cr. as of now.

What is the 52 Week High and Low of Syngene International Ltd?

Answer Field

The 52 Week High and Low of Syngene International Ltd for NSE is ₹ 960.60 and ₹ 607.65 and for BSE is ₹ 960.00 and ₹ 608.00.

How to Buy Syngene International Ltd share?

Answer Field

You can trade in Syngene International Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Syngene International Ltd?

Answer Field

The 1 year returns on the stock has been -7.99%.

What is the Current Share Price of Syngene International Ltd?

Answer Field

Syngene International Ltd share price is for NSE ₹ 634.05 & for BSE ₹ 631 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Syngene International Ltd Share?

Answer Field

The market cap of Syngene International Ltd for NSE ₹ 2,54,89.76 & for BSE ₹ 2,53,67.15 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Syngene International Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Syngene International Ltd share is 54.44.

What is the PB ratio of Syngene International Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Syngene International Ltd share is 115.24.

How to Buy Syngene International Ltd Share?

Answer Field

You can trade in Syngene International Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Syngene International Ltd Share on Bajaj Broking App?

Answer Field

To buy Syngene International Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Syngene International Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|